TY - JOUR
T1 - CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant
AU - Fumagalli, Marcilio Jorge
AU - Castro-Jorge, Luiza Antunes
AU - de Souza, William Marciel
AU - de Azevedo, Patrick Orestes
AU - Hansen, Alana Witt
AU - Gazzinelli, Ricardo Tostes
AU - da Fonseca, Benedito Antônio Lopes
AU - Spilki, Fernando Rosado
AU - Figueiredo, Luiz Tadeu Moraes
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2
Y1 - 2022/2
N2 - The emergence of new SARS-CoV-2 variants represents a constant threat to world public health. The SARS-CoV-2 Delta variant was identified in late 2020 in India; since then, it has spread to many other countries, replacing other predominant lineages and raising concerns about vaccination efficiency. We evaluated the sensitivity of the Delta variant to antibodies elicited by COVID-19 vaccinated (CoronaVac and ChAdOx1) and convalescent individuals previously infected by earlier lineages and by the Gamma variant. No reduction in the neutralizing efficacy of the Delta variant was observed when compared to B lineage and a reduced neutralization was observed for the Gamma variant. Our results indicate that neutralization of the Delta variant is not compromised in individuals vaccinated by CoronaVac or ChAdOx1; however, a reduction in neutralization efficacy is expected for individuals infected by the Gamma variant, highlighting the importance of continuous vaccination even for previously infected individuals.
AB - The emergence of new SARS-CoV-2 variants represents a constant threat to world public health. The SARS-CoV-2 Delta variant was identified in late 2020 in India; since then, it has spread to many other countries, replacing other predominant lineages and raising concerns about vaccination efficiency. We evaluated the sensitivity of the Delta variant to antibodies elicited by COVID-19 vaccinated (CoronaVac and ChAdOx1) and convalescent individuals previously infected by earlier lineages and by the Gamma variant. No reduction in the neutralizing efficacy of the Delta variant was observed when compared to B lineage and a reduced neutralization was observed for the Gamma variant. Our results indicate that neutralization of the Delta variant is not compromised in individuals vaccinated by CoronaVac or ChAdOx1; however, a reduction in neutralization efficacy is expected for individuals infected by the Gamma variant, highlighting the importance of continuous vaccination even for previously infected individuals.
KW - Antibodies
KW - ChAdOx1
KW - Convalescence
KW - CoronaVac
KW - Delta variant
KW - Gamma variant
KW - Neutralization
KW - SARS-CoV-2
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85124229353&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124229353&partnerID=8YFLogxK
U2 - 10.3390/v14020305
DO - 10.3390/v14020305
M3 - Article
C2 - 35215895
AN - SCOPUS:85124229353
SN - 1999-4915
VL - 14
JO - Viruses
JF - Viruses
IS - 2
M1 - 305
ER -
